In combination with chemotherapy, immune checkpoint inhibitors, and therapeutic approaches, developing new therapies against B7-H3 as the “right” tumor antigen and immune checkpoint is a potential treatment strategy for PDAC [55]. This evidence concerns the gene CD276 and neoplasm.